Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

被引:10
|
作者
Klein, Florian G. [1 ]
Granier, Charlene [1 ]
Zhao, Yuling [1 ]
Pan, Qi [1 ,3 ]
Tong, Zhichao [1 ,4 ]
Gschwend, Jurgen E. [1 ]
Holm, Per Sonne [1 ,2 ]
Nawroth, Roman [1 ]
机构
[1] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Med Univ Innsbruck, Dept Oral & Maxillofacial Surg, A-6020 Innsbruck, Austria
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Urol, Shanghai 200240, Peoples R China
[4] Hosp Harbin Med Univ, Dept Urol, 23 Youzheng St, Harbin 150086, Peoples R China
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 05期
关键词
bladder cancer; combination therapy; Talazoparib; Olaparib; Palbociclib; Retinoblastoma protein; apoptosis; chorioallantoic membrane model; CELL LUNG-CANCER; CDK4/6; INHIBITORS; DNA-DAMAGE; BREAST-CANCER; POLYMERASE INHIBITORS; CLINICAL DEVELOPMENT; CYCLIN D1; REPAIR; PARP; ACTIVATION;
D O I
10.3390/jpm11050340
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer
    Sun, Liang
    Lu, Jiaju
    Niu, Zhihong
    Ding, Kejia
    Bi, Dongbin
    Liu, Shuai
    Li, Jiamei
    Wu, Fei
    Zhang, Hui
    Zhao, Zuohui
    Ding, Sentai
    PLOS ONE, 2015, 10 (12):
  • [32] Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
    Chen, Fengquan
    Liu, Chunxi
    Zhang, Jian
    Xu, Wenfang
    Zhang, Yingjie
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (09) : 1241 - 1251
  • [33] Pharmacological significance of palbociclib and its derivatives in cancer treatment and prevention: an update
    Irshad Shagufta
    Laila Zeyad Ahmad
    Noora Ali Bazbouz
    Fatme Ghassan Nasar
    Dana Mahmoud Ibrahim
    undefined Alkheder
    Medicinal Chemistry Research, 2025, 34 (6) : 1237 - 1252
  • [34] Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
    Huang, Weiwei
    Li, Chao
    Chen, Mulan
    Lin, Duanyu
    Wu, Fan
    Chen, Xinhua
    Li, Nani
    Wang, Lili
    Liu, Jian
    ONCOTARGETS AND THERAPY, 2020, 13 : 7785 - 7792
  • [35] The Premature Senescence in Breast Cancer Treatment Strategy
    Milczarek, Malgorzata
    CANCERS, 2020, 12 (07) : 1 - 22
  • [36] Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?
    Darvishi, Ali
    Abdi Dezfouli, Ramin
    Fazaeli, Aliakbar
    Daroudi, Rajabali
    Zandieh, Narges
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (10) : 1201 - 1210
  • [37] Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment
    Zhang, Wenqiang
    Zhang, Jianqiang
    Zhang, Jingwei
    Chu, Jing
    Zhang, Zhenxing
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [38] The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer
    Li, Jingxian
    Shan, Kun
    Huang, Wei
    Su, Qiang
    Qi, Yuanjiong
    Zhang, Zhihong
    Zhu, Jianqiang
    Du, E.
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [39] Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro
    Wang, Li
    Zhang, Yunxin
    Zhao, Jinxia
    Xiao, Erlong
    Lu, Jianzhong
    Fu, Shengjun
    Wang, Zhiping
    TUMOR BIOLOGY, 2014, 35 (11) : 10879 - 10890
  • [40] Natural compounds and combination therapy in colorectal cancer treatment
    Rejhova, A.
    Opattova, A.
    Cumova, A.
    Sliva, D.
    Vodicka, P.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 144 : 582 - 594